4D Pharma PLC
LBPS
LBPS was delisted on the 24th of June, 2022.
1 hedge funds and large institutions have $0 invested in 4D Pharma PLC in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
1.17% less ownership
Funds ownership: 1.17% → 0% (-1.2%)
88% less funds holding
Funds holding: 8 → 1 (-7)
100% less capital invested
Capital invested by funds: $430K → $0 (-$430K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RL
Ruffer LLP
London,
United Kingdom
|
-$320K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$46K |
| 3 |
Capstone Investment Advisors
New York
|
-$25K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$13K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$8K |
LBPS Hedge Fund Activity: Q3 2022 in Review
1 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q3 2022, worth a combined $0 — down 100% from $430K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LBPS and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Ruffer LLP, exiting entirely with an estimated $320K sold.
- 1 institutional investor held 4D Pharma PLC (LBPS) as of Q3 2022, down from 8 in Q2 2022.
- Funds reported $0 of 4D Pharma PLC stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new 4D Pharma PLC positions in Q3 2022 and 7 closed out, a net change of -7 holders.
- The largest 4D Pharma PLC seller in Q3 2022 was Ruffer LLP, an estimated $320K sold.
Based on aggregated 13F filings for Q3 2022.